Health Condition 1: L918- Other hypertrophic disorders of the skin
Conditions
Interventions
Intervention1: intralesional triamcinolone acetonide and hyaluronidase and platelet rich plasma therapy: 4 doses of intralesional triamcinolone acetonide and hyaluronidase injection given at 3 weekly
Sponsors
Dr Baba saheb ambedkar hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed cases of localized keloid aged 18-60 years of either gender. 2. Patients with Vancouver scar score greater than or equal to 4.
Exclusion criteria
Exclusion criteria: 1. Pregnant or Lactating Women 2. Presence of infection (bacterial, viral, or fungal) at or around the keloid site. 3. History of allergy or hypersensitivity to triamcinolone acetonide, hyaluronidase and components of PRP preparation. 4. Patients with History of bleeding disorders (e.g., hemophilia, thrombocytopenia) and Use of anticoagulants or antiplatelet drugs that cannot be discontinued. 5. Patients with Immunocompromised States Including those with HIV/AIDS, on chemotherapy, or long-term immunosuppressive therapy 6. Prior intralesional steroid, hyaluronidase, PRP injections to the same keloid lesion within the last 3 months. 7. Current or recent (within 1 month) systemic corticosteroid or immunosuppressant therapy. 8. Chronic medical conditions that may affect healing like poorly controlled diabetes mellitus , chronic kidney disease and liver dysfunction or cirrhosis 9. Areas where assessment is difficult (e.g., scalp under thick hair, mucosal surfaces) 10. History of keloid excision in the past 3 months. 11. Patients with widespread keloidosis rather than isolated, well-defined keloid lesions. 12. Ear keloid.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in Vancouver Scar Scale below 4Timepoint: baseline, 3 weeks, 6 weeks, 9 weeks and 12 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| to compare the efficacy between two groups as per verbal rating scale , patient satisfaction score at 3 weeks 6 weeks 9 weeks 12 weeksTimepoint: baseline 3 weeks 6 weeks 9 weeks 12 weeks;to compare the side effect profile between two groups at 3 weeks 6 weeks 9 weeks 12 weeks follow upTimepoint: 3 weeks 6 weeks 9 weeks 12 weeks;to compare relapse rate at 24 weeks in both groupsTimepoint: 24 weeks | — |
Countries
India
Contacts
Public ContactBrinda K
Baba Saheb Ambedkar medical college and hospital
Outcome results
None listed